Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Assets: 2019-2025

Historic Non-Current Assets for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $58.6 million.

  • C4 Therapeutics' Non-Current Assets fell 42.99% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 42.99%. This contributed to the annual value of $91.8 million for FY2024, which is 12.76% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Non-Current Assets is $58.6 million, which was down 18.35% from $71.8 million recorded in Q2 2025.
  • C4 Therapeutics' Non-Current Assets' 5-year high stood at $212.5 million during Q1 2022, with a 5-year trough of $50.9 million in Q2 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $102.8 million (2024), whereas its average is $97.2 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 846.60% in 2021, then slumped by 44.68% in 2023.
  • Over the past 5 years, C4 Therapeutics' Non-Current Assets (Quarterly) stood at $181.1 million in 2021, then decreased by 20.87% to $143.3 million in 2022, then dropped by 26.54% to $105.3 million in 2023, then declined by 12.76% to $91.8 million in 2024, then slumped by 42.99% to $58.6 million in 2025.
  • Its Non-Current Assets stands at $58.6 million for Q3 2025, versus $71.8 million for Q2 2025 and $87.0 million for Q1 2025.